Skip to main content
. 2017 Jul 27;8(43):73372–73386. doi: 10.18632/oncotarget.19637

Figure 3. An LSD1 inhibitor (GSK-LSD1) attenuates proliferation and inhibits key targets in HSC-3 cells.

Figure 3

A. Inhibition of LSD1 by different inhibitors (n = 6 replicates per treatment), including tranylcypromine (TCP), GSK-LSD1 and LSD1-C76 impaired the proliferation of HSC-3 and CAL-27 cells; B. Microarray and gene set enrichment analysis (GSEA) (n = 3 replicates per treatment) revealed that GSK-LSD1 inhibits key genes and C. GSEA indicated that GSK-LSD1 inhibits specific signaling pathways. Statistical analyses were performed with unpaired Student’s t-tests. The significant differences are indicated with * P-value<0.05 in HSC3 cells and #P-value<0.05 in CAL-27 cells.